{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:03:39Z","timestamp":1771473819063,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40264-021-01097-5","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T07:02:31Z","timestamp":1631948551000},"page":"1099-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience"],"prefix":"10.1007","volume":"44","author":[{"given":"Lu\u00eds M.","family":"Magalh\u00e3es","sequence":"first","affiliation":[]},{"given":"Raquel","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Vieira","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-5078","authenticated-orcid":false,"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"issue":"11","key":"1097_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1046\/j.1535-7597.2001.00013.x","volume":"16","author":"PV Motika","year":"2016","unstructured":"Motika PV, Spencer DC. Treatment of epilepsy in the elderly. Curr Neurol Neurosci Rep. 2016;16(11):96. https:\/\/doi.org\/10.1046\/j.1535-7597.2001.00013.x.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"7","key":"1097_CR2","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/ph3072090","volume":"3","author":"A Wahab","year":"2010","unstructured":"Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals (Basel). 2010;3(7):2090\u2013110. https:\/\/doi.org\/10.3390\/ph3072090.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1097_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1525-5050(03)00037-4","volume":"4","author":"E Kutluay","year":"2003","unstructured":"Kutluay E, McCague K, D\u2019Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav. 2003;4(2):175\u201380. https:\/\/doi.org\/10.1016\/S1525-5050(03)00037-4.","journal-title":"Epilepsy Behav"},{"key":"1097_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2147\/CIA.S50819","volume":"10","author":"A Romigi","year":"2015","unstructured":"Romigi A, Femia EA, Fattore C, Vitrani G, Di Gennaro G, Franco V. Zonisamide in the management of epilepsy in the elderly. Clin Interv Aging. 2015;10:931\u20137. https:\/\/doi.org\/10.2147\/CIA.S50819.","journal-title":"Clin Interv Aging"},{"key":"1097_CR5","unstructured":"CHMP\/EWP\/566\/98 rev 3, Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. 2018 https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf. Accessed Jun 2021."},{"issue":"Suppl 3","key":"1097_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1528-1157.2001.042suppl.3055.x","volume":"42","author":"G Kr\u00e4mer","year":"2001","unstructured":"Kr\u00e4mer G. Epilepsy in the elderly: some clinical and pharmacotherapeutic aspects. Epilepsia. 2001;42(Suppl 3):55\u20139. https:\/\/doi.org\/10.1046\/j.1528-1157.2001.042suppl.3055.x.","journal-title":"Epilepsia"},{"issue":"Suppl","key":"1097_CR7","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.4103\/0972-2327.128645","volume":"17","author":"JN Acharya","year":"2014","unstructured":"Acharya JN, Acharya V. Epilepsy in the elderly: special considerations and challenges. Ann Indian Acad Neurol. 2014;17(Suppl):S18-26. https:\/\/doi.org\/10.4103\/0972-2327.128645.","journal-title":"Ann Indian Acad Neurol"},{"issue":"6","key":"1097_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2147\/NDT.S1026","volume":"3","author":"JJ Poza","year":"2007","unstructured":"Poza JJ. Management of Epilepsy in the elderly. Neuropsychiatr Dis Treat. 2007;3(6):723\u20138. https:\/\/doi.org\/10.2147\/NDT.S1026.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10 Suppl 4","key":"1097_CR9","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1212\/WNL.63.10_suppl_4.S40","volume":"63","author":"GK Bergey","year":"2004","unstructured":"Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology. 2004;63(10 Suppl 4):S40\u20138. https:\/\/doi.org\/10.1212\/WNL.63.10_suppl_4.S40.","journal-title":"Neurology"},{"key":"1097_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.seizure.2017.04.003","volume":"48","author":"A G\u00f3mez-Ib\u00e1\u00f1ez","year":"2017","unstructured":"G\u00f3mez-Ib\u00e1\u00f1ez A, Serratosa JM, Guillam\u00f3n E, Garc\u00e9s M, Gir\u00e1ldez BG, Toledo M, Salas-Puig J, L\u00f3pez-Gonz\u00e1lez FJ, Rodr\u00edguez-Uranga J, Castillo A, Mauri JA, Camacho JL, L\u00f3pez-Gom\u00e1riz E, Giner P, Torres N, Palau J, Molins A, Villanueva V. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: case series. Seizure. 2017;48:53\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2017.04.003.","journal-title":"Seizure."},{"issue":"6","key":"1097_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ane.12162","volume":"128","author":"E Trinka","year":"2013","unstructured":"Trinka E, Giorgi L, Patten A, Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128(6):422\u20138. https:\/\/doi.org\/10.1111\/ane.12162.","journal-title":"Acta Neurol Scand"},{"key":"1097_CR12","unstructured":"European Medicines Agency. Zebinix (eslicarbazepine acetate): EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zebinix-epar-product-information_en.pdf. Accessed Jun 2021."},{"key":"1097_CR13","unstructured":"Sunovion Pharmaceuticals Inc. Aptiom (eslicarbazepine acetate) tablets, for oral use: US prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022416s011lbl.pdf. Accessed Jun 2021."},{"issue":"12","key":"1097_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s40264-017-0576-4","volume":"40","author":"H Gama","year":"2017","unstructured":"Gama H, Vieira M, Costa R, Gra\u00e7a J, Magalh\u00e3es LM, Soares-da-Silva P. Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: from clinical studies to 6 years of post-marketing experience. Drug Saf. 2017;40(12):1231\u201340. https:\/\/doi.org\/10.1007\/s40264-017-0576-4.","journal-title":"Drug Saf"},{"issue":"12","key":"1097_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40266-018-0602-y","volume":"35","author":"R Costa","year":"2018","unstructured":"Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P. Safety, tolerability and efficacy of eslicarbazepine acetate as adjunctive therapy in patients aged \u2265 65 years with focal seizures. Drugs Aging. 2018;35(12):1109\u201317. https:\/\/doi.org\/10.1007\/s40266-018-0602-y.","journal-title":"Drugs Aging"},{"issue":"2","key":"1097_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40120-019-0137-0","volume":"8","author":"C Lawthom","year":"2019","unstructured":"Lawthom C, Bermejo P, Campos D, McMurray R, Villanueva V. Effectiveness and safety\/tolerability of eslicarbazepine acetate in epilepsy patients aged \u2265 60 versus < 60 years: a subanalysis from the Euro-Esli Study. Neurol Ther. 2019;8(2):491\u2013504. https:\/\/doi.org\/10.1007\/s40120-019-0137-0.","journal-title":"Neurol Ther."},{"key":"1097_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106478","volume":"169","author":"E Andermann","year":"2021","unstructured":"Andermann E, Rosenfeld W, Penovich P, Rogin J, Cendes F, Carreno M, et al. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (\u226560 years) and younger (18\u201359 years) adults. Epilepsy Res. 2021;169: 106478. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106478.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1097_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","volume":"48","author":"C Elger","year":"2007","unstructured":"Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48(3):497\u2013504. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.00984.x.","journal-title":"Epilepsia"},{"issue":"3","key":"1097_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","volume":"50","author":"C Elger","year":"2009","unstructured":"Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50(3):454\u201363. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01946.x.","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"1097_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","volume":"89","author":"E Ben-Menachem","year":"2010","unstructured":"Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2\u20133):278\u201385. https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.01.014.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1097_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","volume":"120","author":"A Gil-Nagel","year":"2009","unstructured":"Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial onset seizures. Acta Neurol Scand. 2009;120(5):281\u20137. https:\/\/doi.org\/10.1111\/j.1600-0404.2009.01218.x.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"1097_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/epi.1289","volume":"56","author":"MR Sperling","year":"2015","unstructured":"Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, Kowacs PA, Hong SB, Cheng H, Blum D, Nunes T, Soares-da-Silva P, 304 Study Team. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244\u201353. https:\/\/doi.org\/10.1111\/epi.1289.","journal-title":"Epilepsia"},{"issue":"2","key":"1097_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/epi.13993","volume":"59","author":"E Trinka","year":"2018","unstructured":"Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, L\u00f6ffler K, Rocha JF, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia. 2018;59(2):479\u201391. https:\/\/doi.org\/10.1111\/epi.13993.","journal-title":"Epilepsia"},{"key":"1097_CR24","unstructured":"Bial\u2013Portela & Ca, S.A. Data on file; 2017."},{"issue":"11","key":"1097_CR25","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/epi.16366","volume":"60","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Trinka E, Giovane CD, Nardone R, Silvestrini M, Brigo F. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis. Epilepsia. 2019;60(11):2245\u201354. https:\/\/doi.org\/10.1111\/epi.16366.","journal-title":"Epilepsia"},{"issue":"1","key":"1097_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ane.13025","volume":"139","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Zaccara G, Giovannelli F, Grillo E, Nardone R, Silvestrini M, Trinka E, Brigo F. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139(1):33\u201341. https:\/\/doi.org\/10.1111\/ane.13025.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1097_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.seizure.2010.12.015","volume":"20","author":"KJ Werhahn","year":"2011","unstructured":"Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Kr\u00e4mer G. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure. 2011;20(4):305\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2010.12.015.","journal-title":"Seizure."},{"issue":"3","key":"1097_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00415-016-8338-2","volume":"264","author":"SD Shorvon","year":"2017","unstructured":"Shorvon SD, Trinka E, Steinhoff BJ, Holtkamp M, Villanueva V, Peltola J, Ben-Menachem E. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies. J Neurol. 2017;264(3):421\u201331. https:\/\/doi.org\/10.1007\/s00415-016-8338-2.","journal-title":"J Neurol"},{"key":"1097_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.yebeh.2018.01.020","volume":"80","author":"V Jalihal","year":"2018","unstructured":"Jalihal V, Shankar R, Henley W, Parrett M, Tittensor P, McLean BN, Ahmed A, Sander JW. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav. 2018;80:365\u20139. https:\/\/doi.org\/10.1016\/j.yebeh.2018.01.020.","journal-title":"Epilepsy Behav"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01097-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T08:10:25Z","timestamp":1632643825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01097-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01097-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,18]]},"assertion":[{"value":"5 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sponsor Bial\u2013Portela & C<sup>a<\/sup>, S.A., Coronado, Portugal, conducted this analysis and was responsible for the study design; the collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lu\u00eds M. Magalh\u00e3es, Raquel Costa, Mariana Vieira, Joana Moreira, Helena Gama, and Patr\u00edcio Soares-da-Silva are employees of Bial\u2013Portela & C\u00aa, S.A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the manuscript conception and design. All authors read the draft versions and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All procedures performed in studies involving human participants in all participating countries were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies reported in this manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}